Skip to main content
INSPInspire Medical Systems, Inc.Hold5.0·$46.95+3.28%
INSP · Why this verdict

Why Inspire Medical Systems (INSP) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score5.0/10
ConfidenceHIGH
MacroNEUTRAL

Thesis pillars

A forward P/E of 31.5x versus a trailing P/E of approximately 9x implies the market is pricing in a sharp earnings contraction of roughly 70%; if this contraction arrives as expected, the forward multiple is not as cheap as headline comparisons suggest.

Stable
Warnings
Expectation
If the thesis is wrong, forward earnings estimates should be revised upward and the forward P/E should compress below 15x over the next four quarters.

CounterThe four-quarter beat streak suggests management has consistently guided below its actual delivery; the feared 70% contraction may incorporate worst-case peak assumptions that could prove more durable than consensus expects.

The company has beaten earnings estimates in each of the past four quarters with an average quarterly surprise exceeding 180%, a pattern consistent with consistently under-promising and over-delivering on guidance.

Stable
Earnings
Expectation
A fifth consecutive earnings beat would extend the streak and signal that forward guidance remains conservative relative to operational capacity.

CounterThe bear case calls for a roughly 70% earnings decline from the current peak; if that contraction materializes, even disciplined guidance management cannot prevent the beat streak from snapping as the earnings base resets sharply lower.

Short interest at 17% of float with 8.3 days to cover reflects significant market skepticism about the company's ability to sustain its performance through the anticipated earnings cycle; elevated short positioning adds downward pressure if long holders begin to exit.

Stable
Risk breakdown
Expectation
Short interest falling below 8% would signal that skeptics are covering and the bear thesis is losing conviction.

CounterVolume accumulation (rising on-balance volume) suggests some buyers are stepping in at current levels; high short interest can become a coiled spring if the next earnings report surprises to the upside.

The stock is trading below its 200-day moving average with the trend slope at -11.2% per 30 days, a confirmed downtrend; while the MACD is improving, the recovery signal has not yet been confirmed and the stock sits at the bottom of its 52-week range.

Stable
Momentum breakdown
Expectation
Price reclaiming and holding above the 200-day moving average for four consecutive weeks, with the slope turning flat or positive, would confirm a technical reversal.

CounterThe MACD is improving and RSI sits near 45, not at oversold extremes; the momentum dimension passed its minimum gate, suggesting the downtrend may be stabilizing rather than accelerating.

A debt-to-equity ratio of 3.7x has been flagged as a constraint on the investment case; at this leverage level, the company has limited financial cushion if the anticipated earnings decline materializes and cash generation softens.

Stable
Bear case
Expectation
Debt-to-equity falling below 2.0x through debt repayment or earnings-driven equity growth would meaningfully improve financial resilience.

CounterThe Piotroski F-Score of 8 out of 9 and a current ratio well above 1.0 suggest near-term solvency is not at risk; elevated leverage is more a constraint on strategic flexibility than an indicator of immediate financial distress.

TrendMatrix Research · core thesis

Engine thesis — one sentence

Inspire Medical Systems has delivered four consecutive quarters of exceptional earnings beats with an average surprise exceeding 180%, yet the forward earnings picture implies a severe contraction — the forward P/E of 31.5x is roughly 3.4 times the trailing multiple — while the stock trades in a confirmed technical downtrend, carries a debt-to-equity ratio of 3.7x, and faces 17% short interest; the reward-to-risk ratio of 1.49-to-1 falls short of standard entry criteria, making patience the appropriate posture.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Per-dimension breakdown

Value

4.8/10data confidence 83%
ComponentSub-score
P/E8.9
P/S9.3
EV/EBITDA2.2
Fwd P/E2.9
Analyst target4.0
  • Forward P/E: 36.6x

Quality

5.5/10data confidence 100%
ComponentSub-score
ROE6.1
ROA2.6
Gross margin10.0
Op margin0.0
Net margin7.2
Current ratio6.7
FCF quality5.0
Moat5.8
Rule of 403.0
Piotroski F8.9
  • Earnings quality warning: 65% FCF/NI
  • Rule of 40: 11 (fail)
  • Strong Piotroski F-Score: 8/9

Growth

2.9/10data confidence 33%
ComponentSub-score
Rev growth2.9

Momentum

6.8/10data confidence 100%
ComponentSub-score
RSI3.3
MACD10.0
OBV10.0
MA position6.0
Volume4.7
  • Volume accumulation (rising OBV)
  • Below 200-MA, MA slope -8.7%/30d — confirmed downtrend

Sentiment

5.9/10data confidence 100%
ComponentSub-score
LLM sentiment6.5
Analyst rating5.0
Price target6.5

Insider

5.0/10data confidence 50%
ComponentSub-score
materiality5.0
holder change5.1
  • Insider selling (low materiality) — $175,945 (0.013% of mkt cap)

Peer rank

6.1/10data confidence 80%
ComponentSub-score
value rank8.9
quality rank8.6
growth rank1.7
  • Attractive P/E vs peers
  • Superior ROE vs peers

Technical

1.5/10data confidence 100%
ComponentSub-score
bollinger0.0
support resistance1.0
52w position0.0
gap5.0

Risk (lower is worse)

5.0/10data confidence 100%
ComponentSub-score
short interest7.4
days to cover7.4
volatility1.0
put call9.4
implied vol0.0
beta8.7
debt equity1.3
  • Short squeeze setup: 16% short, quality 7.5
  • High IV: 87%
  • Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.3/10data confidence 100%
ComponentSub-score
erm1.5
earnings history10.0
earnings timing5.0
surprise avg10.0
news activity5.0
  • Estimates down -5.1% (30d)
  • Perfect beat streak: 4Q

How the verdict was assembled

Engine trigger

Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING).

Engine technical detail
verdict_path: L4:PATH_F_SELL|L3:NEWS_MOD=+1
Passed (6)
  • MOMENTUM:6.8>=5.5
  • INSIDER:OK
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:31d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • ASYMMETRY:-0.3=NEGATIVE
Warning (2)
  • DEATH_CROSS:momentum=6.8>=5.0 recovering
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.27
Upside
-4.1%
Downside
15.0%
Sizing output
AVOID

SetupRecovery Death cross but MACD improving, RSI 67

EdgeNo clear edge No clear edge identified

SuitabilitySpeculative Drawdown -68% (>40% off 52w high)

Investment implication

The F-path SELL output reflects an overall score of 3.5 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 6.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.3=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.27 — supplementary context, not the trigger for this path.

The strongest dimensions are Momentum at 6.8, Catalyst at 6.3, and Peer rank at 6.1; the weakest are Technical at 1.5, Growth at 2.9, and Value at 4.8. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.27 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Earnings Beat Streak Excellence

    Trip ifEPS surprise falls below 0% for 2 consecutive quarters, ending the beat streak.

  • P2Cyclical Peak Valuation Risk

    Trip ifForward earnings estimates are revised upward such that the forward P/E compresses below 15x within 4 quarters.

  • P3High Short Interest Headwind

    Trip ifShort interest falls below 8% of float over 2 consecutive reporting periods, indicating the bear thesis has been substantially abandoned.

  • P4Confirmed Technical Downtrend

    Trip ifPrice reclaims and holds above the 200-day moving average for 4 consecutive weeks, with the 30-day slope reversing to flat or positive.

  • P5Elevated Leverage Limits Cushion

    Trip ifDebt-to-equity ratio falls below 2.0x through debt repayment or equity issuance.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks INSP Why this verdict